New Cancer Drug Boosts Blood Pressure(Page 3) In the statement, Pfizer added that, "Lower incidences of cardiovascular effects have been observed in subsequent randomized Phase 3 prospective Sutent [sunitinib] studies in both renal cell carcinoma and gastrointestinal stromal tumor[s]." That includes a lower incidence of events such as congestive heart failure, impaired heart function, and high blood pressure that were noted in Chen's retrospective analysis, the company said. More information For more on sunitinib, visit the U.S. National Library of Medicine. Related Links
advertisement
| ||
What's HOTGet our free newsletter
PR Newswire |
 |
The drkoop.com URL and web site are not associated with C. Everett Koop, M.D., former Surgeon General of the United States.
By using this service, you accept our Terms of Use. Please read them. The consumer health information on drkoop.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2004-2008. The HealthCentral Network, Inc. All rights reserved.